Nasdaq:US$18.72 (-0.96) | HKEX:HK$29.65 (-0.70) | AIM:£3.04 (-0.09)
新闻中心及演示文稿
上一篇文章   |   下一篇文章
演示文稿, 科学出版物 | 2012-06-01

ASCO 2012: Phase I study of safety and pharmacokinetics of fruquintinib, a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases in patients with advanced solid tumors